Beam Therapeutics Inc (BEAM)
24.18
-0.14
(-0.56%)
USD |
NASDAQ |
May 28, 16:00
24.18
0.00 (0.00%)
After-Hours: 18:36
Beam Therapeutics SG&A Expense (Quarterly): 26.72M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 26.72M |
| December 31, 2023 | 43.26M |
| September 30, 2023 | 25.41M |
| June 30, 2023 | 24.66M |
| March 31, 2023 | 23.49M |
| December 31, 2022 | 22.68M |
| September 30, 2022 | 21.82M |
| June 30, 2022 | 24.06M |
| March 31, 2022 | 19.25M |
| December 31, 2021 | 17.77M |
| September 30, 2021 | 15.77M |
| June 30, 2021 | 13.40M |
| Date | Value |
|---|---|
| March 31, 2021 | 10.27M |
| December 31, 2020 | 8.354M |
| September 30, 2020 | 7.502M |
| June 30, 2020 | 6.937M |
| March 31, 2020 | 6.812M |
| December 31, 2019 | 6.16M |
| September 30, 2019 | 5.487M |
| June 30, 2019 | 4.977M |
| March 31, 2019 | 3.929M |
| December 31, 2018 | 3.711M |
| September 30, 2018 | 2.834M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
4.977M
Minimum
Jun 2019
43.26M
Maximum
Dec 2023
16.74M
Average
16.77M
Median
SG&A Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 1.836B |
| Perspective Therapeutics Inc | 5.878M |
| Electromed Inc | 8.374M |
| Xtant Medical Holdings Inc | 20.24M |
| Asensus Surgical Inc | 8.016M |